Promise vs. uptake: genuine clinical gains preserved; unresolved health targets and directly observed fallout also recorded. 10 sources examined · 7 carriers · 3 contextual/contrary.

CONTRARY DATA: The strongest contrary evidence is substantive. Bristol Myers Squibb’s Phase 3 ALOFT-IPF trial met the primary endpoint with the 60 mg admilparant dose: significantly less forced-vital-capacity decline over 52 weeks versus placebo. The higher dose did not meet the same endpoint, and regulatory approval and long-term patient outcomes remain prospective. In a published randomized trial of 283 non-insulin-treated adults with type 2 diabetes, continuous glucose monitoring improved glycated hemoglobin and time in target range over six months, with 21 percentage points more time in range than routine care. A randomized ulcerative-colitis Phase 2b study found clinical remission at week 12 in 30% on the 400 mg icotrokinra dose versus 11% on placebo; clinical response rates were 63% versus 27%. These are actual measured patient outcomes and must not be erased as “only next steps.” The W1 threshold is stable, durable completion-side output within the domain, not domain-wide success. At the endpoints tested here, slowed progression is not restored lung function or a durable cure; six-month improved glucose control required continued monitoring, not documented sustained remission independent of it; and the 12-week colitis remission is a real remission endpoint but does not establish stable long-term remission in this fixed window. No source in the carrier/contrary set establishes W1 for the specific assignment targets. W1 remains on the contrary-data runway for future longitudinal results.

Next scan: Saturday October 24, 2026 · 3:30 PM EDT · Relationships / Loneliness. Scored forecast P≈0.95 · HIT; next forecast P≈0.95 · 21-record basis · MODERATE. Prospective judgmental estimate, not certainty.

The Gravity Array uses global scans, public-source data, probability matrices, predictive pattern recognition, and tracking instruments to show where that fallout is appearing — globally and personally. Each domain is a receiver field; the Array combines them into one weekly readout.

Two scales, one name. Gravity is the observatory — the public institution tracking the structural detection. The Gravity Array is the instrument inside it. The observatory keeps watch; the Array detects.

Why "Array" is correct, not cosmetic: an array is defined by multi-detection — many receivers combined into one instrument, no single element being the instrument itself. The ATA combines 42 dishes; the Gravity Array combines its domains. Gravity's receivers are domains, not dishes — but the structure is identical: distributed scanning across many elements, compared for recurrence, combined into one readout. That is what makes it an array in the same sense SETI's is.